1. Home
  2. LCNB vs MDWD Comparison

LCNB vs MDWD Comparison

Compare LCNB & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LCNB Corporation

LCNB

LCNB Corporation

HOLD

Current Price

$15.97

Market Cap

234.5M

Sector

Finance

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$17.45

Market Cap

212.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCNB
MDWD
Founded
1877
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
234.5M
212.1M
IPO Year
1999
2013

Fundamental Metrics

Financial Performance
Metric
LCNB
MDWD
Price
$15.97
$17.45
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
17.7K
68.2K
Earning Date
04-22-2026
05-20-2026
Dividend Yield
5.43%
N/A
EPS Growth
68.04
N/A
EPS
1.63
N/A
Revenue
$6,445,000.00
N/A
Revenue This Year
$8.50
$48.92
Revenue Next Year
$3.66
$35.04
P/E Ratio
$9.71
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.75
$14.90
52 Week High
$17.89
$22.51

Technical Indicators

Market Signals
Indicator
LCNB
MDWD
Relative Strength Index (RSI) 43.50 55.82
Support Level $15.92 $16.68
Resistance Level $16.44 $18.49
Average True Range (ATR) 0.48 0.56
MACD -0.08 0.03
Stochastic Oscillator 14.29 80.00

Price Performance

Historical Comparison
LCNB
MDWD

About LCNB LCNB Corporation

LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: